UPMC Sells Oncology Analytics Firm To Elsevier

Using analytics tools to improve cancer treatment can be very hard. That struggle is exemplified by the problems faced by IBM Watson Health, which dove into the oncology analytics field a few years ago but made virtually no progress in improving cancer treatment. With any luck, however, Via Oncology will be more successful at moving the needle in cancer care. The company, which offers decision support for cancer treatment and best practices in cancer care management, was just acquired by information analytics firm Elsevier, which plans to leverage the company’s technology to support its healthcare business. Elsevier’s Clinical Solutions group works to improve patient outcomes, reduce clinical errors and optimize cost and reimbursements for providers. Via Oncology, a former subsidiary of the University of Pittsburgh Medical Center, develops and implements clinical pathways for cancer care. Via Oncology spent more than 15 years as part of UPMC prior to the acquisition. Via Oncology’s Via Pathways tool relies on evidence-based content to create clinical algorithms covering 95% of cancer types treated in the US. The content was developed by oncologists. In addition to serving as a basis for algorithm development, Via Oncology also shares the content with physicians and their staff through its Via Portal, a decision support tool which integrates with provider EMRs. According to Elsevier, Via Pathways addresses more than 2,000 unique patient presentations which can be address...
Source: EMR and HIPAA - Category: Information Technology Authors: Tags: EHR Electronic Health Record Electronic Medical Record EMR Genomic Medicine Genomics Health Care Healthcare Healthcare AI HealthCare IT Hospital EHR Patients Personalized Medicine Precision Medicine Elsevier Oncology Analytic Source Type: blogs